Here's Biogenes. They've just raised a $5.7M Series A! This Malaysian biotech develops synthetic antibodies (aka, aptamers), biosensors, and diagnostics tests.
Investor check. The funds were raised from Pembangunan Ekuiti (PESB), a local Malaysian VC firm.
🧐 What they do?
Aptamer development. They develop new kinds of synthetic antibodies (aka, aptamers). Two of their developed aptamers are being tested in clinical trials at hospitals in Malaysia, with others coming up soon!
Usually, animal-harvested antibodies are used in most applications — medical research and even human treatments. But aptamers are seen as a viable alternative!
Sensors and portable diagnostics. They also design and supply biosensor products and diagnostics solutions.
Platforms. They also build tech platforms, like the APTCAD platform, which allows people to start initial designs for aptamers online.
🔜 What's next
They'll be investing in a medical-grade manufacturing facility, advancing their technology portfolio and expanding their sales outreach to SEA and beyond!
See ya soon! They've already signed agreements to enter the Philippines and Indonesia this year.
The newsletter that keeps you up-to-date on the top stories on tech and business in Southeast Asia. It's fun, quick and free.